Purpose: To describe late apical relapse of a choroidal melanoma at the site of fine needle aspiration biopsy 10 years following successful treatment with 125I brachytherapy. Methods: Retrospective case report of a 78-year-old male presenting 10 years following successful 125I brachytherapy for a choroidal melanoma with a medium-sized nodular amelanotic tumor recurrence at the site of the prior tumor biopsy. Results: Fundus photography and B-scan ultrasound documented the findings at presentation at our institution. The patient was followed closely for 8 weeks while information was retrieved from the treating institution. During this short period, there was significant apical tumor growth. Additionally, there was a clear clinical change compared to the last documented photos from 5 years prior at the treating institution. Enucleation was recommended. Pathological analysis confirmed the diagnosis of recurrent choroidal melanoma at the apex of the treated lesion, at the site of prior biopsy. Systemic surveillance was negative for metastatic disease. Conclusion: Current literature suggests the majority of choroidal melanoma recurrences occur within 5 years following treatment. However, this case of recurrence 10 years after brachytherapy emphasizes the importance of life-long ophthalmic care for these patients. Additionally, this case demonstrates the possibility of a rare recurrence at a prior biopsy site.

1.
Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR; Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings: COMS report No. 18. Arch Ophthalmol 2001;119:969-982.
2.
Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG; Collaborative Ocular Melanoma Study Group (COMS Group): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, IV: local treatment failure and enucleation in the first 5 years after brachytherapy: COMS report No. 19. Ophthalmology 2002;109:2197-2206.
3.
Quivey JM, Char DH, Philips TL, Weaver KA, Castro JR, Kroll SM: High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993;26:613-618.
4.
Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW: Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 2002;120:933-940.
5.
Char DH, Kroll S, Phllips TL, Quivey JM: Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology 2002;109:1850-1854.
6.
Gallie BL, Simpson R, Saakyan S, Amiryan A, Valskiy V, Finger PT, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Català J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusöz M, Luyten GPM, Singh A, Schachat AP, Suzuki S, Aihara Y; The Ophthalmic Oncology Task Force: Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology 2016;123:86-91.
7.
Chang MY, McCannel TA: Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013;97:804-811.
8.
Berry JL, Dandapani SV, Stevanovic M, Lee TC, Astrahan M, Murphree AL, Kim JW: Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol 2013;131:1435-1442.
9.
Chang MY, Kamrava M, Demanes DJ, Leu M, Agazaryan N, Lamb J, Moral JN, Almanzor R, McCannel TA: Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. Ophthalmology 2012;119:1073-1077.
10.
Bellerive C, Aziz HA, Bena J, Wilkinson A, Suh JH, Plesec T, Singh AD: Local failure after episcleral brachytherapy for posterior uveal melanoma: patterns, risk factors, and management. Am J Ophthalmol 2017;177:9-16.
11.
Sánchez-Tabernero S, García-Alvarez C, Muñoz-Moreno MF, Diezhandino P, Alonso-Martínez P, de Frutos-Baraja JM, López-Lara F, Saornil MA: Pattern of local recurrence after I-125 episcleral brachytherapy for uveal melanoma in a Spanish referral ocular oncology unit. Am J Ophthalmol 2017;180:39-45.
12.
Karlsson UL, Augsburger JJ, Shields JA, Markoe AM, Brady LW, Woodleigh R: Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology 1989;96:382-388.
13.
Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD: Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol 2004;137:893-900.
14.
Sellam A, Desjardins L, Barnhill R, Plancher C, Asselain B, Savignoni A, Pierron G, Cassoux N: Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes. Am J Ophthalmol 2016;162:28- 34.e1.
15.
Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC: Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997;19:22-28.
16.
Bagger M, Andersen MT, Heegaard S, Andersen MK, Kiilgaard JF: Transvitreal retinochoroidal biopsy provides a representative sample from choroidal melanoma for detection of chromosome 3 aberrations. Invest Ophthalmol Vis Sci 2015;56:5917-5924.
17.
McCannel TA, Chang MY, Burgess BL: Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology 2012;119:606-610.
18.
Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL: Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol 2016;100:456-462.
19.
Angi M, Kalirai H, Taktak A, Hussain R, Groenewald C, Damato BE, Heimann H, Coupland SE: Prognostic biopsy of choroidal melanoma: an optimized surgical and laboratory approach. Br J Ophthalmol 2017;1143-1146.
20.
Char DH, Kroll S, Phillips TL: Uveal melanoma. Growth rate and prognosis. Arch Ophthalmol 1997;115:1014-1018.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.